Introduction {#s1}
============

Exacerbations of COPD are defined as an acute worsening of symptoms beyond the daily variability seen in patients with COPD and are associated with increased airway and systemic inflammation [@pone.0107381-Wedzicha1]. Exacerbations are commonly triggered by viruses or bacteria, although other environmental trigger factors such as air pollution are recognised [@pone.0107381-Wedzicha1], [@pone.0107381-Papi1]. The ECLIPSE study has recently identified a frequent exacerbation phenotype present across all GOLD airflow limitation stages, characterized by developing at least 2 exacerbations every year over a 3 year follow up [@pone.0107381-Hurst1]. In the same study there were subjects at all GOLD stages who did not exacerbate at all over three years. Patients with more frequent exacerbations are known to have worse quality of life and increased mortality [@pone.0107381-Seemungal1], [@pone.0107381-SolerCatalua1].

The cellular and molecular mechanisms responsible for the increased susceptibility to exacerbations in the frequent exacerbation phenotype are poorly understood. If the cascade of inflammatory events that result in the clinical development of an exacerbation episode is centred in the lungs, it is likely that there are differences in the airway cells of patients with the frequent exacerbation phenotype compared with those that do not have exacerbations. However, if the cascade represents a generalized systemic response to pathogens or other trigger factors, it is likely that there will be differences that could be detected in immune cells in the systemic circulation.

We hypothesized that there are differences in the gene expression profile in the blood and airway cells of frequent exacerbators compared with non-exacerbators. To test this hypothesis we studied well characterized COPD subjects in the ECLIPSE cohort. We investigated the gene expression profile pattern associated with the frequent exacerbation phenotype in sputum and blood cells.

Methods {#s2}
=======

Subjects {#s2a}
--------

ECLIPSE is a 3-year multicentre longitudinal study to identify novel endpoints in COPD; the methodology has been previously described [@pone.0107381-Vestbo1]. Sputum induction was performed and blood samples obtained in a subset of 148 COPD ex-smokers at 14 sites at the start of the study. Samples of sufficient quality for gene array analysis were obtained from 138 of these subjects. These subjects were subsequently followed up for 3 years, and the number of exacerbations was quantified. Blood samples obtained from a different group of 215 COPD patients participating in ECLIPSE were used for PCR analysis.

Ethics statement {#s2b}
----------------

ECLIPSE was ethically approved by the local ethics committee at each participating centre; Clinicaltrials.gov identifier NCT00292552; GSK Study Identifier SCO104960. All participants provided written informed consent.

Sputum induction and processing {#s2c}
-------------------------------

The methods for sputum induction and processing have been previously described [@pone.0107381-Singh1] and are included in the supporting information ([File S1](#pone.0107381.s001){ref-type="supplementary-material"}).

Whole blood collection {#s2d}
----------------------

Using standard venipuncture techniques, 2.5 mls of blood was drawn into each of two PAXGene blood collection tubes. The isolation of RNA from these samples is described in the supporting information ([File S1](#pone.0107381.s001){ref-type="supplementary-material"}).

Microarray processing {#s2e}
---------------------

The performance of microarrays is described in the supporting information ([File S1](#pone.0107381.s001){ref-type="supplementary-material"}).

Real time PCR {#s2f}
-------------

RNA was isolated and processed by Aros Applied Biotechnology (Denmark) as described in the supporting information ([File S1](#pone.0107381.s001){ref-type="supplementary-material"}).

Statistical analysis {#s2g}
--------------------

Patients with frequent exacerbations were defined as those who had experienced two or more exacerbations requiring oral corticosteroids and/or antibiotics or were hospitalised within a year, for each of the 3 years of the study as previously defined in the ECIPSE study [@pone.0107381-Hurst1]. This group was compared to patients with no exacerbations during this time period. Univariate analysis used a p value of \<0.01 to define significant differences between groups, and gene expression fold change (FC) levels as indicated in the text. Individual genes were mapped to Genego pathways (GeneGo, St. Joseph, MI, <http://www.genego.com/metacore.php>), with p≤0.01 and FDR\<0.05 used to identify significant pathways. The gene array data is accessible at <geo@ncbi.nlm.nih.gov> (GEO ID GSE4837 and GSE22148).

A linear model analysis of variance was also used to identify a set of genes associated with the frequent exacerbator phenotype; The analysis was adjusted for age, gender and batch by including these variables as terms in the model. Previous subject reported exacerbation history was also used as one of the variables in the model. The history of exacerbations after one year was used to create the model, as there were more subjects with either frequent or zero exacerbations after one year (44 versus 62 respectively) compared to three years (17 vs 29 respectively). The subjects were randomly split into a training set and a validating set using the data at year 1 as shown in [Fig. 1](#pone-0107381-g001){ref-type="fig"}. The training set included 29 subjects with frequent exacerbations and 41 with zero exacerbations and for the validating set these numbers were 15 and 21 respectively. 100 training sets were used to create 100 predictive models. Stepwise logistic regression was used to select the most significant predictors; The model structure was (ln\[p/(1-p)\] =  *α*+*β~1~*(predictor1) + *β~2~*(predictor2).... + e), p is the probability that the subject will have 2 or more exacerbations and p/(1-p) is the "odds ratio" and ln\[p/(1-p)\] is the log odds ratio, or "logit". Each model was checked against the 1000 validating sets to determine its prediction accuracy. One of the best performing models was then checked against the whole sample set of 44 frequent exacerbators compared to 62 zero exacerbators.

![Identification of a set of genes in blood associated with the frequent exacerbator phenotype; multivariate analysis using micro-array data 1 year follow up data (n = 106), followed by univariate analysis of 3 year follow up data (n = 46) and univariate analysis of a different population (n = 215) by PCR.\
FE =  frequent exacerbators; ZE  =  zero exacerbators.](pone.0107381.g001){#pone-0107381-g001}

Real time PCR data were similarly analyzed using a linear model analysis of variance. A covariate was also included to account for any change in expression due to the RNA loading of the samples. This covariate was represented by the scores from the first principal component obtained from a PCA analysis of the two housekeeper genes.

Results {#s3}
=======

Microarray data {#s3a}
---------------

The demographic and clinical characteristics at baseline for the 138 COPD patients whose sputum and blood samples were used for gene arrays are shown in the supporting information (Table S1 in [File S1](#pone.0107381.s001){ref-type="supplementary-material"}). After 3 years of follow up, there were 117 patients who completed the study with a documented exacerbation history; the demographic details of these subjects are shown in [Table 1](#pone-0107381-t001){ref-type="table"}; 17 patients were frequent exacerbators and 29 patients had zero exacerbations.

10.1371/journal.pone.0107381.t001

###### Demographics of the COPD subjects for microarray analysis.

![](pone.0107381.t001){#pone-0107381-t001-1}

                                All    Zero   Intermediate   Frequent
  ---------------------------- ------ ------ -------------- ----------
  N                             117     29         71           17
  GOLD Stage II (%)              51     55         55           29
  GOLD Stage III (%)             41     38         39           53
  GOLD Stage IV (%)              8      7          6            18
  Male (%)                       66     69         65           65
  Mean age                      64.9   63.2       65.7         64.8
  Mean pack years               46.8   52.0       45.3         43.7
  Percent Predicted FEV1 (%)    50.3   51.8       51.7         42.3
  LABA (%)                      78.6   58.6       83.1         94.1
  Inhaled corticosteroid (%)    75.2   55.2       80.3         88.2
  Blood WBC                     7.5    7.5        7.3          8.2
  Blood neutrophil count        4.9    4.8        4.8          5.5
  Blood eosinophil count        0.24   0.21       0.24         0.27
  Blood leukocyte count         1.87   2.05       1.82         1.80
  Blood monocyte count          0.46   0.43       0.44         0.59

Exacerbations were defined over a 3 year follow up; frequent denotes 2 or more exacerbations each year, zero denotes no exacerbations in any year, and intermediate denotes patients who did not fit the frequent or zero exacerbation phenotype. Blood counts are mean values (X10^9^ cells/L).

There were no differences between groups in the blood counts (p\>0.05 for all comparisons between groups). A total of 150 genes (166 probesets) were differentially expressed in blood at the level of\>±1.5 FC (p≤0.01) between frequent compared to zero exacerbators. In contrast, in the sputum cells, there were only 6 genes (9 probesets) differentially expressed between these groups. The most highly regulated genes in blood and sputum cells are shown in [Table 2](#pone-0107381-t002){ref-type="table"}, with a full list of genes differentially expressed\>±1.5 FC in the supporting information (Table S2 in [1](#pone.0107381.s001){ref-type="supplementary-material"}).

10.1371/journal.pone.0107381.t002

###### The 10 most highly regulated genes in sputum and blood from microarray analysis; a positive fold change  =  increase in frequent exacerbators compared to zero exacerbators, a negative fold change  =  decrease in frequent exacerbators compared to zero exacerbators.
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  Gene Name      Affy. ID      Fold change   p value   Sample
  ----------- --------------- ------------- --------- --------
  LOC284723      232245_at        1.71        0.009    Sputum
  ANKRD28        213035_at        1.71        0.008    Sputum
  LOC284723    1559977_a\_at      1.65        0.009    Sputum
  LDHAL6B        210712_at        1.55        0.001    Sputum
  MIA          206560_s\_at       1.53        0.008    Sputum
  OASL           205660_at        −1.54       0.009    Sputum
  RHCE         215819_s\_at       2.25        0.010    Blood
  CCNA1          205899_at        2.23        0.009    Blood
  ITGB2        236988_x\_at       2.21        0.008    Blood
  COL4A3         222073_at        −2.05       0.001    Blood
  FCRL1          235982_at        −2.06      \<0.001   Blood
  FCRL2        221239_s\_at       −2.06      \<0.001   Blood
  CD200        209583_s\_at       −2.09       0.002    Blood
  HLA-DQB1     212999_x\_at       −2.22       0.009    Blood
  TCL6         219840_s\_at       −2.59      \<0.001   Blood
  HLA-DQA1       236203_at        −3.27       0.003    Blood

Affy. ID  =  affymatrix identification number. There was no overlap between sputum and blood for highly expressed genes.

The intermediate group of patients (n = 71) who had exacerbations but did not meet the criteria for inclusion in the frequent exacerbation group had only 21 genes differentially regulated in blood compared to zero exacerbators; there was a greater separation of gene expression in the frequent exacerbation group compared to zero exacerbators (150 genes). The genes differentially expressed in blood from the intermediate group compared to zero exacerbators (21 genes) and compared to frequent exacerbators (20 genes) are shown in the supporting information (Tables S3 and S4 in [File S1](#pone.0107381.s001){ref-type="supplementary-material"}). [Fig. 2](#pone-0107381-g002){ref-type="fig"} shows that from the 21 genes differentially expressed in intermediate group compared to zero exacerbators, 4 were also differentially expressed in the frequent exacerbators compared to zero exacerbators (listed in supporting information).

![Venn diagram showing the number of differentially regulated genes in blood (fold change +/−1.5 and p\<0.01) between frequent exacerbators (F), the intermediate group (I), and zero exacerbators (Z); for example, F vs I denotes number of differentially regulated genes between frequent exacerbators and the intermediate group.](pone.0107381.g002){#pone-0107381-g002}

Pathway analysis {#s3b}
----------------

As there were relatively fewer gene expression changes observed in the sputum cells of frequent exacerbators compared to zero exacerbators, the rest of the analysis focused on whole blood gene expression. Genego pathway analysis was performed on 811 genes with FC\>±1.2 between frequent compared to zero exacerbators. There were 35 significant pathways (p≤0.01, FDR\<0.05) where at least 4 genes were regulated, including 14 apoptosis pathways, 8 immune response pathways and 5 cell development pathways; these pathways are shown in the supporting information (Table S5 in [File S1](#pone.0107381.s001){ref-type="supplementary-material"}). The 5 most highly regulated pathways are shown in [Table 3](#pone-0107381-t003){ref-type="table"}, and included 2 apoptosis signalling pathways (ceramide and lymphotoxin beta receptor \[LTBR\] signalling) and 3 lymphocyte signalling pathways (inducible T-cell costimulator \[ICOS\] and CD28 signalling in T cells, and B cell receptor signalling).

10.1371/journal.pone.0107381.t003

###### GeneGo pathway mapping of the microarray data for the comparison of zero vs frequent exacerbators; the 5 most highly regulated pathways are shown.

![](pone.0107381.t003){#pone-0107381-t003-3}

  Significance ranking                       Pathway Name from GENEGO                      Genes    P value      Affy. ID      Fold Change   P value   Gene Name
  ---------------------- ---------------------------------------------------------------- ------- ----------- --------------- ------------- --------- -----------
  1                          Apoptosis and survival_Ceramides signaling pathway 3072       8/46    0.0000010     222880_at        −1.37       0.009      AKT3
                                                                                                                 209364_at        1.34        0.005       BAD
                                                                                                               211833_s\_at       1.21        0.002       BAX
                                                                                                                 203685_at        −1.29      \<0.001     BCL2
                                                                                                                 200766_at        1.25        0.004      CTSD
                                                                                                                 229415_at        −1.48      \<0.001     CYCS
                                                                                                                 226046_at        −1.40       0.007      MAPK8
                                                                                                                 235252_at        1.24        0.004      KSR1
  2                             Immune response_ICOS pathway in T-helper cell 619          8/46    0.0000045     222880_at        −1.37       0.009      AKT3
                                                                                                                 209364_at        1.34        0.005       BAD
                                                                                                                 206545_at        −1.48       0.002      CD28
                                                                                                               1555766_a\_at      1.25        0.004      GNG2
                                                                                                                 226878_at        −1.40      \<0.001    HLA-DOA
                                                                                                                 236203_at        −3.27       0.003    HLA-DQA1
                                                                                                               212999_x\_at       −2.22       0.009    HLA-DQB1
                                                                                                                 210439_at        −1.50       0.002      ICOS
                                                                                                                 228976_at        −1.47       0.007     ICOSLG
                                                                                                                 202490_at        −1.37      \<0.001     IKBKB
                                                                                                               216944_s\_at       −1.37       0.005      ITPR1
                                                                                                                 228442_at        −1.33       0.006     NFATC2
                                                                                                                 204484_at        −1.30      \<0.001    PIK3CA
  3                                       Immune response_CD28 signaling                   8/54    0.000016      222880_at        −1.37       0.009      AKT3
                                                                                                                 209364_at        1.34        0.006       BAD
                                                                                                                 206545_at        −1.48       0.002      CD28
                                                                                                               216944_s\_at       −1.37       0.004      ITPR1
                                                                                                                 226046_at        −1.40       0.007      MAPK8
                                                                                                                 228442_at        −1.33       0.006     NFATC2
                                                                                                               209615_s\_at       1.29        0.003      PAK1
                                                                                                                 204484_at        −1.30      \<0.001    PIK3CA
  4                                      Immune response_BCR pathway 655                   8/54    0.000016      222880_at        1.37        0.009      AKT3
                                                                                                                 209364_at        1.34        0.005       BAD
                                                                                                                 203685_at        −1.29      \<0.001    BCL2L1
                                                                                                               207655_s\_at       −1.49      \<0.001     BLNK
                                                                                                               206398_s\_at       −1.67       0.002      CD19
                                                                                                                 204581_at        −1.62       0.001      CD22
                                                                                                               205544_s\_at       −1.79      \<0.001      CR2
                                                                                                                 212827_at        −1.42       0.002      IGHM
                                                                                                               216944_s\_at       −1.37       0.005      ITPR1
                                                                                                                 228442_at        −1.33       0.006     NFATC2
                                                                                                                 204484_at        −1.30      \<0.001    PIK3CA
  5                       Apoptosis and survival_Lymphotoxin-beta receptor signaling 740   7/41    0.000021    211554_s\_at       1.28       \<0.001     APAF1
                                                                                                               211833_s\_at       1.21        0.002       BAX
                                                                                                                 229415_at        −1.48      \<0.001     CYCS
                                                                                                                 203005_at        1.25        0.008      LTBR
                                                                                                                 226046_at        −1.40       0.007      MAPK8
                                                                                                                 207907_at        1.29        0.007     TNFSF14
                                                                                                                 204352_at        −1.32       0.002      TRAF5

The number of genes regulated within each pathway are shown.

Within the apoptosis pathways, the well recognised pro-apoptotic genes BAD, BAX and LTBR had increased expression, while the anti-apoptotic gene BCL2 had decreased expression, indicating a shift towards pro-apoptotic signalling. Within the lymphocyte signalling pathways, there was decreased expression of genes involved in T cell activation such as the co-stimulatory molecules CD28 and ICOS, the transcription factors NFATC2 and AKT3 and HLA genes that encode MHC proteins responsible for antigen presentation to T cells. B cell activation genes also showed decreased expression, including CD19, complement receptor 2 (CR2) and B-cell linker protein (BLNK), although the B cell regulatory protein CD22 had increased expression. There was also decreased expression of other proteins involved in B cell function such as the FC like receptor (FCLR) family members FCLR1, 2 and 5.

Multivariate analysis {#s3c}
---------------------

Multivariate analysis of the gene array data was performed to identify a set of genes most closely associated with the frequent exacerbator phenotype. The 17 and 29 patients followed over three years was an insufficient sample size to create a training and validation set. As described in the methods and [Fig. 1](#pone-0107381-g001){ref-type="fig"}, the clinical history of exacerbations after 1 year was used to create the training and validation set, as there were more subjects who experienced no exacerbations and frequent exacerbations in this time period (62 and 44 respectively). Multivariate analysis was performed using 368 genes with FC\>±1.2, p≤0.01 between these groups. The best performing model included these 6 genes; SYT6, ARHGEF10, PHPT1, MGC31963, LAF4 and B3GNT ([Table 4](#pone-0107381-t004){ref-type="table"}).

10.1371/journal.pone.0107381.t004

###### Gene expression changes in the 6 gene panel identified by microarray analysis using the phenotype data after 1 year.

![](pone.0107381.t004){#pone-0107381-t004-4}

              Microarray; 1 year phenotype   Microarray; 3 year phenotype   PCR; 3 year phenotype                     
  ---------- ------------------------------ ------------------------------ ----------------------- ---------- ------- ----------
  B3GNT1                  −1.4                         \<0.0001                     −1.5            \<0.0001   −1.2    \<0.0001
  SYT6                    1.4                          \<0.0001                       1              0.881       1      0.693
  LAF4                    −1.5                         \<0.0001                     −1.7             0.0007    −1.4    \<0.0001
  ARHGEF10                −1.4                          0.013                       −1.3             0.0439    −1.4    \<0.0001
  MGC31963                1.4                           0.0001                       1.6            0.00046      1      0.5601
  PHPT1                   1.2                           0.003                        1.4             0.007     −1.3    \<0.0001
  FCL5                    −1.5                           0.01                       −1.83            0.003     −1.16    0.131
  PLCL2                   −1.3                          0.002                       −1.43            0.006     −1.65    0.0008

The gene expression changes using the phenotype data after 3 years from the microarray population and PCR population are shown. Positive fold change  =  increase in frequent exacerbators compared to zero exacerbators, negative fold change  =  decrease in frequent exacerbators compared to zero exacerbators.

The expression of these 6 genes between frequent and zero exacerbators using 3 year follow up clinical history is shown in [Table 4](#pone-0107381-t004){ref-type="table"}; ARHGEF10, PHPT1, MGC31963, LAF4 and B3GNT were significantly differentially expressed between groups, but not SYT6.

PCR analysis {#s3d}
------------

PCR analysis of the 5 genes shown by microarray to be differentially expressed in frequent and zero exacerbators after 3 years (ARHGEF10, PHPT1, MGC31963, LAF4 and B3GNT) was performed in a different group of 215 subjects (see [Table 5](#pone-0107381-t005){ref-type="table"} for demographic details), including 75 with zero exacerbations and 140 with frequent exacerbations in the 3 year follow up period. PLCL2 and FCL5, which were also differentially expressed on microarray, and SYT6 were also analysed by PCR.

10.1371/journal.pone.0107381.t005

###### Demographics of the COPD subjects for PCR analysis.
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                                None   Frequent
  ---------------------------- ------ ----------
  N                              75      140
  Stage II (%)                   44       30
  Stage III (%)                  31       42
  Stage IV (%)                   25       28
  Male (%)                       65       56
  Mean age                       63       63
  Mean pack Years                56       48
  Percent predicted FEV1 (%)     48       42
  Current smokers (%)           38.6     37.6
  LABA (%)                       45       89
  Inhaled corticosteroid (%)     51       94
  Blood WBC                     7.7      8.2
  Blood neutrophil count         5       5.4
  Blood eosinophil count        0.24     0.26
  Blood leukocyte count         0.44     0.52
  Blood monocyte count          2.02     1.95

Exacerbations were defined over a 3 year follow up; frequent denotes 2 or more exacerbations each year, zero denotes no exacerbations in any year, and intermediate denotes patients who did not fit the frequent or zero exacerbation phenotype. Blood counts are mean values (X10^9^ cells/L).

B3GNT1, LAF4, ARHGEF10 and PLCL2 expression were significantly different between frequent and zero exacerbators (see [Table 4](#pone-0107381-t004){ref-type="table"}). SYT6, MGC31963 and FCL5 did not achieve statistical significance, while PHPT1 had a complete reversal of signal. B3GNT, LAF4 and ARHGEF10 were retested as a model in this population; these 3 genes predicted the frequent exacerbation phenotype with sensitivity and specificity of 88% and 33% respectively, with the values improving to 91% and 81% respectively when the exacerbation history in the previous year was considered. Modelling previous exacerbation history alone gave sensitivity and specificity of 90% and 83% respectively.

Discussion {#s4}
==========

This study has demonstrated differences in the gene expression profile of COPD patients with frequent exacerbations compared to those with no exacerbations over a 3 year period in ECLIPSE. There were 150 genes differentially expressed in the circulating cells of the two groups, with only 6 differentially regulated genes in sputum cells. This suggests alterations in systemic immune function that contribute to the frequent exacerbation phenotype rather than a specific pulmonary immune defect.

Our results suggest that future investigations into the pathophysiology of COPD exacerbations should focus on changes that occur in the systemic immune system. We have not proved mechanistically that the changes observed here are the cause or consequence of frequent exacerbations, but nevertheless provide a starting point for further investigations into the gene expression differences observed. Microarray gene expression profiling is often "hypothesis generating", and our results have generated a number of hypotheses regarding potentially dysregulated immunological pathways in COPD frequent exacerbators. We have provided a degree of validation of our findings by performing PCR analysis in a different group of COPD patients. The microarray gene expression findings reported here serve as a basis for future investigations of potential mechanisms involved in COPD exacerbations.

A subset of the microarray gene expression findings were investigated in a different, and larger, group of patients by PCR. Four out of seven microarray genes that showed significant differences in blood using the 3 year follow up data were also significantly different in the PCR analysis in a separate population. Microarray gene expression analysis often produces false positive results due to multiple testing, so it is desirable to validate the findings using different techniques and/or a different sampling population. A major strength of this study is the use of two cohorts for replication. The PCR analysis indicates that many of the micro-array results are not false positive findings. Our pathway analysis describes a large number of genes involved in lymphocyte signalling and apoptosis pathways, and the presence of some false positive data would not change these overall findings.

Our findings are not due to sampling or methodological issues; using the same sputum samples from the subjects in this study, we have recently shown a large set of genes associated with disease severity defined by FEV~1~ or the degree of emphysema at the FC level of 2 [@pone.0107381-Singh1]; 277 genes were differentially regulated in severe compared to moderate COPD, and 198 genes were differentially regulated according to the degree of emphysema respectively. In stark contrast, there were no induced sputum genes regulated at this FC level in frequent exacerbators compared to zero exacerbators. Furthermore, the gene expression differences in whole blood were not due to differences in the composition of the leukocytes, as the differential white cell counts were similar in patients with frequent exacerbations compared to those with zero exacerbations.

Exacerbations are often caused by respiratory pathogens, such as viruses and bacteria [@pone.0107381-Wedzicha1], [@pone.0107381-Papi1]. It is thought that an exaggerated and/or prolonged immune response to pathogens in susceptible COPD patients leads to an acute exacerbation. One might reasonably assume that patients with frequent exacerbations would have changes within the pulmonary immune system that pre-dispose to an exaggerated immune response after exposure to a respiratory pathogen. Alternatively, the abnormality could be systemic in nature. Our results suggest dysregulation of systemic immune function in COPD frequent exacerbators rather than dysfunction limited to the lungs.

Systemic immunological response {#s4a}
-------------------------------

There was decreased expression of the T-cell receptor co-stimulatory molecules CD28 and ICOS, and GeneGo analysis identified multiple changes within these signalling pathways. Co-stimulatory signals through CD28 and ICOS enhance T cell activation following T-cell receptor stimulation [@pone.0107381-Simpson1]. The expression of HLA genes that encode MHC class II was also reduced, suggesting a diminished capacity for antigen presentation to T cells [@pone.0107381-Sundberg1]. Reduced antigen presentation coupled with reduced co-stimulation indicates a decreased adaptive immune response in frequent exacerbators. Furthermore, there was also decreased expression of T cell transcription factors such as NFATC2 in frequent exacerbators; this transcription factor is involved in T cell cytokine production [@pone.0107381-Simpson1], [@pone.0107381-Macian1], and reduced gene expression levels may be a downstream consequence of decreased T cell receptor signalling. There were other T cell specific genes that were highly regulated ([Table 2](#pone-0107381-t002){ref-type="table"}), including decreased expression of\> 2 FC for CD200 which is known to suppress inflammatory lymphocyte responses [@pone.0107381-Rygiel1] and TCL-6 [@pone.0107381-Saitou1] which is expressed in T cell leukaemia cells. The altered expression of so many genes involved in T cell signalling strongly suggests that altered T cell function plays a mechanistic role in the frequent exacerbator phenotype.

There was decreased expression of B cell activation genes including the co-receptors CD19 and CR2, and the downstream signalling molecule BLNK [@pone.0107381-Ying1], [@pone.0107381-Hasler1]. CR2, also known as CD21, binds to complement attached to immune complexes; CR2 expression is decreased in auto-immune diseases [@pone.0107381-Erdei1], which may represent physiological down-regulation rather than the primary cause of auto-immunity. In the context of COPD exacerbations, it is also possible that reduced B cell signalling is a primary physiological mechanism that causes susceptibility to exacerbations, or a physiological response to repeated or prolonged infection. The expression of the B cell regulatory protein CD22 [@pone.0107381-Kawasaki1] was increased in frequent exacerbators, again compatible with negative regulation of B cell function.

There is evidence of impaired T-cell receptor signalling in autoimmune diseases [@pone.0107381-Maurice1], [@pone.0107381-Jury1]. Similarly, it has recently been shown that the expression of T-cell receptor signalling components is reduced in pulmonary CD8 cells from COPD patients [@pone.0107381-Grundy1]. Our findings now suggest that peripheral blood T and B cells are in a state of decreased activation in COPD patients with frequent exacerbations. This may reduce their ability to act effectively during infections, thus leading to an increased susceptibility to exacerbations.

Pulmonary lymphoid follicles numbers are increased in COPD patients [@pone.0107381-Hogg1]; These organised structures facilitate antigen presentation, cytokine secretion and antibody production by B cells. The exact nature of the antigen presentation is unknown, and may be self-antigens or pathogen derived antigens. It would be interesting to know if there is also reduced activation of cells within lymphoid follicles of COPD exacerbators.

Cell death and tissue repair {#s4b}
----------------------------

Apoptosis is the process of programmed cell death that occurs as part of normal tissue homeostasis. We observed a shift towards pro-apoptotic mechanisms in peripheral blood samples of frequent exacerbators, as the expression of the pro-apoptotic genes BAD [@pone.0107381-Zinkel1], BAX [@pone.0107381-Zinkel1] and LTBR [@pone.0107381-Ware1] was increased, while anti-apoptotic BCL2 [@pone.0107381-Zinkel1] expression was decreased. This suggests that immune cells in the peripheral circulation of frequent exacerbators have an increased rate of apoptosis. There is evidence of increased apoptosis in the lungs of COPD patients [@pone.0107381-Demedts1], which may be related to increased levels of oxidative stress. A balance of increased tissue apoptosis with reduced clearance by immune cells can lead to increased tissue inflammation. Immune cells cannot participate in the normal immune response while undergoing programmed cell death; this may be an important mechanism contributing to a reduced immune response against pathogens in frequent exacerbators.

Other pathway genes {#s4c}
-------------------

[Table 2](#pone-0107381-t002){ref-type="table"} shows some relatively highly regulated genes that may be of biological relevance in COPD. For example, CCNA1 encodes the protein cyclin A1 which is involved in cell cycle processes [@pone.0107381-Marlow1] and was increased in frequent exacerbators. Increased CCNA1 may indicate increased cell cycle in blood cells capable of cell division, such as lymphocytes. There was also increased ITGB2 expression; this gene encodes CD18 which is involved in leukocyte adhesion [@pone.0107381-Weckbach1].

The 3 gene panel confirmed by PCR were B3GNT1 which encodes beta-1,3-N-acetylglucosaminyltransferase enzyme involved in poly-N-acetyllactosamine synthesis [@pone.0107381-Lee1], LAF4 which is a transcription factor involved in lymphoid development [@pone.0107381-Ma1], and ARHGEF10 which is a rho GTPase involved in cell signalling events [@pone.0107381-Chaya1]. The expression of these genes was reduced in frequent exacerbators. Reduced LAF4 expression is compatible with our other findings of decreased lymphocyte signalling in frequent exacerbators. It is unclear if our findings regarding B3GNT1 and ARHGEF10 are indicative of mechanisms involved in frequent exacerbations, or biomarkers of patients who have such events. Further studies of the function of these genes, and the other significantly regulated genes reported here, in COPD patients would shed light on their potential biological roles. It would also be of value to study the protein expression levels of these genes to provide further validation of our findings.

Comparison with previous studies {#s4d}
--------------------------------

There are other studies that have investigated gene expression profiles in COPD peripheral blood using isolated cells [@pone.0107381-Bhattacharya1], [@pone.0107381-Bahr1]. The novelty of our work is that we have investigated gene expression associated with exacerbation history; previous studies have not addressed this question. The interpretation of these previous studies is often restricted by relatively small sample sizes. However, a recent large study (n = 211) investigated gene expression associated with the presence and severity of COPD [@pone.0107381-Bahr1]. Interestingly, there were some findings in common with our study; T cell receptor signalling was found to be altered, with PLCL2, which is involved in signal transduction processes, being one of the differentially regulated genes [@pone.0107381-Otsuki1].

Multivariate analysis {#s4e}
---------------------

Multivariate modelling identified 3 genes in blood samples that could be used with high sensitivity (91%) to predict the frequent exacerbator phenotype. The sensitivity of this 3 gene panel was as good as the clinical history (90%). A previous history of exacerbations is a good predictor of future exacerbations [@pone.0107381-SolerCatalua1], and our results confirm that clinical history is reliable and sensitive in this regard. We do not suggest this gene panel could replace the clinical history. However, there are situations where this gene panel may be useful, such as confirmation of the history in clinical practice when deciding whether to start a patient on a therapy targeted against exacerbations, or in clinical trials to objectively confirm the frequent exacerbator phenotype.

Strengths of the study {#s4f}
----------------------

This study had several strengths. First, it included a derivative and a validating cohort of very well characterized patients followed prospectively using the same procedure for data gathering and analyses. Second, the simultaneous measurement of gene expression in two anatomical compartments (sputum and blood) provides information about the potential contribution of local versus systemic changes in the genesis of COPD exacerbations. Our data suggests that it is important to not only study the lungs, but also the systemic compartment when attempting to explain the pathogenesis of exacerbations. The differentially regulated genes reported here in the blood can be further investigated to understand the altered immunobiology in COPD frequent exacerbators.

Limitations of the study {#s4g}
------------------------

There are several potential limitations. First, the timing of sample collection in relation to exacerbations. We were extremely careful to collect samples from patients during the stable state, at least 4 weeks after an exacerbation, to avoid gene expression changes that were due to episodes of exacerbation themselves. The lack of induced sputum signals indicates that we were successful in this regard. Secondly, it could be argued that therapy, most notably inhaled corticosteroids, could have influenced the gene expression. More COPD subjects were taking inhaled corticosteroids in the frequent exacerbator phenotype (88.2% - see [Table 1](#pone-0107381-t001){ref-type="table"}), likely because treatment guidelines suggest that these drugs should be prescribed to such patients. Whole blood gene expression in the intermediate group who had similar inhaled corticosteroid usage (80.3%) compared with the frequent exacerbators, but had a lower level of exacerbations, showed only 21 genes that were different compared to zero exacerbators, which is lower than the comparison of frequent exacerbators with zero exacerbators (150 genes). This demonstrates that any inhaled corticosteroid effect on gene expression was low and did not account for the major differences in gene expression. Thirdly, it could be argued that the study has little clinical applicability. However, improved understanding of pathways associated with frequent exacerbations may lead to the development of novel therapies targeting immune defects in this subset of patients. Our results provide insights into a number of pathways that provide the basis for future investigations.

It would be of interest to study the genes reported here longitudinally to observe changes over time. It is probable that gene expression patterns in COPD patients change over time, and this may be associated with a change in clinical phenotype such as frequency of exacerbations.

Conclusions {#s5}
===========

We have demonstrated changes in the systemic immune function associated with the frequent exacerbator phenotype. There was down-regulation of lymphocyte function and a shift towards pro-apoptosis mechanisms in the peripheral blood of this phenotype. These may be important mechanisms that are responsible for the frequent exacerbation events observed in these patients and potentially their modulation could lead to a decrease in the number and/or duration of the episodes. More importantly, this study shows that the frequent exacerbator phenotype may have a biological underpinning and is not the product of simple perception or type of health delivery bias.

Supporting Information {#s6}
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